AUG 7, 2026 · PHASE 3 TRIAL
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
ClinicalTrials.gov
This is a Phase 3 RCT registration with no posted results; the study is actively recruiting and outcome data are not yet available for clinical interpretation.
Reported
Primary endpointInvasive Disease-Free Survival (iDFS)
Follow-up durationUp to ~77 months
Planned enrollment1530